

INFORMAZIONI PERSONALI

ORCID ID: 0000-0002-7693-4825

Anno di nascita: 1978

Nazionalità: Italiana

POSIZIONE LAVORATIVA ATTUALE

2012 –2019 Ricercatrice medico presso il Laboratorio di Biochimica - Biotecnologie e Diagnostica Avanzata, Fondazione IRCCS Policlinico San Matteo, Pavia

TITOLI DI STUDIO

13/02/2012 Dottorato di Ricerca in Bioingegneria e Bioinformatica, Università degli Studi di Pavia

29/10/2008 Specialità in Medicina Interna, Università degli Studi di Pavia (votazione: 50/50)

13/07/2003 Laurea in Medicina e Chirurgia, Università degli Studi di Pavia (votazione: 110/110 *cum laude*)

ALTRI TITOLI

Cultore della Materia in Biochimica Generale (da dicembre 2019)

Abilitazione Scientifica Nazionale, Il fascia per Biochimica Generale (BIO/10) (dal 31 marzo 2017)

POSIZIONI LAVORATIVE PRECEDENTI

2008 – 2011 Dottoranda, Dipartimento di Bioingegneria e Bioinformatica, Università di Pavia

Agosto 2009 Visiting collaborator presso Novartis Vaccines and Diagnostics, Emeryville, CA, USA

2003 – 2008 Specializzanda, Divisione di Medicina Interna, Università di Pavia, Italy

2005 - 2006 Visiting scholar presso Amyloid Treatment and Research Center and Center for Biological Mass Spectrometry, Boston University School of Medicine, Boston, MA, USA.

Luglio 2002 Internato di ricerca presso Molecular Biology Laboratory, MRC, Cambridge, UK

INSEGNAMENTO E SEMINARI

- 2019 Seminario durante il convegno formativo "Approccio Multidisciplinare all'Amiloidosi Cardiaca", Università degli Studi di Genova e Ospedale San Martino, Genova
- 2018 Seminario durante il convegno formativo Pfizer "Cardiomiopatia Amiloidotica Correlata alla Transtiretina: Focus su Attività Clinico-Diagnostica", Pavia
- 2016 Seminario: "Tecniche di proteomica applicate alla caratterizzazione della sostanza amiloide: cenni metodologici e applicazioni cliniche", corso Cefar "Proteine, dal Laboratorio alla Clinica", Napoli

- 2014 Seminario: "Typing and identification phase: what are the techniques to detect amyloid?" Pfizer Histopathology Masterclass Meeting, Vienna, Austria
- 2014 Seminario: "Applicazioni cliniche della proteomica" nell'ambito del corso "La spettrometria di massa nel laboratorio analisi chimico-cliniche". Università degli studi dell'Insubria, Varese
- 2012 Seminario: "Recenti acquisizioni diagnostiche nelle amiloidosi", nell'ambito del Corso "Nuove prospettive diagnostiche e strategie terapeutiche nel mieloma multiplo e nell'amiloidosi AL", Azienda Ospedaliera Sant'Andrea e Università di Roma Sapienza, Roma
- 2011 Seminario: "Il ruolo attuale della proteomica" nel corso: "La biopsia renale: dall'approccio tradizionale alle nuove metodiche di studio", Università degli Studi di Torino
- 2010 Seminario: "Analisi di miscele proteiche complesse: elettroforesi bidimensionale" nell'ambito del corso "Isoelettrofocalizzazione nell'analisi delle proteine: utilizzo clinico". Università degli studi dell'Insubria, Varese
- 2009 Seminario: "Metabolomica", nell'ambito del corso: "Le proteine: dal laboratorio alla clinica. Nuove metodologie e nuovi scenari clinici". Università degli studi dell'Insubria, Varese
- 2008: Seminario "Approccio proteomico per la scoperta di biomarcatori di tumori: un futuro per la diagnosi precoce e la terapia" nell'ambito del 7° Corso di formazione avanzata "Progressi in Biologia e Medicina": "Nanomedicina: dalle nanostrutture alla terapia personalizzata", Collegio Universitario Ghislieri, Pavia

FUNDING

- 2017-2020: Grant Giovani Ricercatori da Fondazione Cariplo (Titolo: Systemic AL amyloidosis and the heart: molecular and cellular determinants of light chains proteotoxicity; Ruolo: PI; 2 partners)
- 2013-2016: Grant Giovani Ricercatori da Ministero della Salute (Titolo: Investigation of the molecular bases of cardiomyopathy in immunoglobulin light chain (AL) amyloidosis; Ruolo: PI; 3 partners)
- 2013-2014: PI di un progetto sponsorizzato dal consorzio PRIME-XS, finanziato nell'ambito del 7th Framework Programme dell'Unione Europea.
- 2012-2013: Grant Giovani Ricercatori da Amyloidosis Foundation, USA (Titolo: Cardiac AL amyloidosis: a multidisciplinary approach to investigate molecular mechanisms of damage in human cardiac cells; Ruolo: PI).

PREMI E RICONOSCIMENTI

- Presidential award, XVI International Symposium on Amyloidosis, Kumamoto, Japan (2018)
- Travel award, XIV International Symposium on Amyloidosis, Indianapolis, IN, USA (2014)
- Travel award, XIII International Symposium on Amyloidosis, Groningen, The Netherlands (2012)
- Best poster presentation award, XIII International Symposium on Amyloidosis, Groningen, The Netherlands (2012)
- Young investigator award da Fondazione Mintas, Pavia (2012)
- Young investigator fellowship da Collegio Ghislieri, Pavia (2006)
- "Domenico Fenili" poster award dalla Società Italiana di Biochimica Clinica (2004)
- Premio "Federica Bertoglio Emanuel" fellowship da Collegio Ghislieri, Pavia (2004)
- Alunna del Collegio Ghislieri di Pavia (1997 – 2003)

ALTRO

- Iscritta all'albo dei Medici Chirurghi della provincia di Pavia dal 2004
- Eletta come "Member at large" della International Society for Amyloidosis, Marzo 2018

- **Revisore** su invito per le seguenti riviste: American Journal of Hematology, Scientific Reports, Amyloid, PLOS One, Clinical Chemistry and Laboratory Medicine, Physiology, Theranostics, Journal of Proteomics, Journal of Clinical Medicine, Analytical Cellular Pathology, Clinical Biochemistry, Disease Models & Mechanisms.

PRESENTAZIONI SU INVITO

- Invited speaker e moderatore di sessione, XVII International Symposium on Amyloidosis, Tarragona, Spagna, Settembre 2020
- Keynote presentation "Preparation of natural amyloid fibrils: strategies and pitfalls", LINXS Amyloid Workshop: Mind the gaps in amyloid fiber structure analyses, Lund, Svezia, Novembre 2019
- "Proteotoxicity of amyloidogenic cardiotoxic light chains", Miniworkshop PROTEIN MISFOLDING AND AMYLOIDOSIS XIII ; Università degli Studi di Genova, Maggio 2019
- "Reproducing light chain proteotoxicity in animal models: a window on AL cardiomyopathy" XV International Symposium on Amyloidosis, Uppsala, Luglio 2016 (Key presentation nel corso della sessione Animal models in amyloid research)
- "Typing and identification phase: what are the techniques to detect amyloid?" Pfizer Histopathology Masterclass Meeting, Vienna, Ottobre 2014
- "Functional proteomic analysis of the mechanisms of proteotoxicity in cardiac AL amyloidosis" IX Congresso ItPA (Italian Proteomics Association), Napoli, Giugno 2014
- "Early detection of amyloid: Histopathological approaches" ARiA III Symposium, Advances and Research in TTR Amyloidosis, Portogallo, Febbraio 2014
- Presentazione su invito presso Brigham and Women's Hospital (Host: Dr. Ronglih Liao), 2012
- Selected poster presentation, XIII International Symposium on Amyloidosis, Groningen, Olanda, 2012
- Presentazione su invito presso Mayo Clinic, Rochester, MN, USA (Host: Dr. Ahmet Dogan), Maggio 2010
- "Co-Immunoprecipitation as a method for isolating and studying circulating monoclonal free light chains and their interacting proteins in serum", XII International Symposium on Amyloidosis, Roma, 2010
- "Profiling the proteome of amyloid-affected adipose tissue by MudPIT", IV International EURAMY meeting, Amsterdam, 2009.
- "Tissue proteomics in amyloidosis: study of ATTR cases and analysis of myocardium", III International EURAMY meeting, Berlino, 2008
- Selected poster presentation: "Immunoaffinity purification and mass spectrometry characterization of serum amyloidogenic free light chains in AL amyloidosis", 40° Congresso Nazionale della Società Italiana di Biochimica Clinica e Biologica Molecolare Clinica (SiBioc), Rimini, 2008
- Selected poster presentation: "Usefulness of urine immunofixation electrophoresis in the diagnosis of AL amyloidosis", 39° Congresso Nazionale della Società Italiana di Biochimica Clinica e Biologica Molecolare Clinica (SiBioc), Rimini, 2007
- "A Proteomic Approach to the Molecular Diagnosis of Systemic Amyloidoses", 39° Congresso Nazionale della Società Italiana di Biochimica Clinica e Biologica Molecolare Clinica (SiBioc), Rimini, 2007
- "A proteomic approach to the study of systemic amyloidoses", XI International Symposium on Amyloidosis, Boston, MA, USA, 2006

PUBBLICAZIONI:

64 pubblicazioni indicizzate (Pubmed, aggiornato al 17 giugno 2020)

H-index: 24 (Scopus, aggiornato al 17 giugno 2020)

1. Caccialanza R, Cereda E, Klersy C, Milani P, Cappello S, Martinelli V, Turri A, Basset M, Borioli V, Nuvolone M, Caraccia M, **Lavatelli F**, Masi S, Lobascio F, Foli A, Merlini G, Palladini G. Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis. *Amyloid*. 2020:1-6.
2. Maritan M, Romeo M, Oberti L, Sormanni P, Tasaki M, Russo R, Ambrosetti A, Motta P, Rognoni P, Mazzini G, Barbiroli A, Palladini G, Vendruscolo M, Diomede L, Bolognesi M, Merlini G, **Lavatelli F****, Ricagno S**. Inherent Biophysical Properties Modulate the Toxicity of Soluble Amyloidogenic Light Chains. *J Mol Biol*. 2020;432(4):845-860
3. Maritan M, Ambrosetti A, Oberti L, Barbiroli A, Diomede L, Romeo M, **Lavatelli F**, Sormanni P, Palladini G, Bolognesi M, Merlini G, Ricagno S. Modulating the cardiotoxic behaviour of immunoglobulin light chain dimers through point mutations. *Amyloid*. 2019;26(sup1):105-106.
4. Oberti L, Maritan M, Rognoni P, Barbiroli A, **Lavatelli F**, Russo R, Palladini G, Bolognesi M, Merlini G, Ricagno S. The concurrency of several biophysical traits links immunoglobulin light chains with toxicity in AL amyloidosis. *Amyloid*. 2019;26(sup1):107-108.
5. Ami D, Mereghetti P, Foli A, Tasaki M, Milani P, Nuvolone M, Palladini G, Merlini G, **Lavatelli F****, Natalello A**. ATR-FTIR Spectroscopy Supported by Multivariate Analysis for the Characterization of Adipose Tissue Aspirates from Patients Affected by Systemic Amyloidosis. *Anal Chem*. 2019;91(4):2894-2900.
6. Mishra S, Joshi S, Ward JE, Buys EP, Mishra D, Mishra D, Morgado I, Fisch S, **Lavatelli F**, Merlini G, Dorbala S, MacRae CA, Liao R. Zebrafish model of amyloid light chain cardiotoxicity: regeneration versus degeneration. *Am J Physiol Heart Circ Physiol*. 2019;316(5):H1158-H1166.
7. Swuec P*, **Lavatelli F***, Tasaki M, Paissoni C, Rognoni P, Maritan M, Brambilla F, Milani P, Mauri P, Camilloni C, Palladini G, Merlini G, Ricagno S, Bolognesi M. Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient. *Nat Commun*. 2019;10(1):1269.
8. Tasaki M, Milani P, Foli A, Verga L, Obici L, Basset M, Bozzola M, Ferraro G, Nuvolone M, Morbini P, Capello G, Ueda M, Obayashi K, Paulli M, Ando Y, Merlini G, Palladini G, **Lavatelli F**. Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: prospective study in 206 patients. *Blood*. 2019. pii: blood.2019000420.
9. **Lavatelli F**, Merlini G. Proteomics with Mass Spectrometry Imaging: Beyond Amyloid Typing. *Proteomics*. 2018(7):e1700353.
10. Oberti L, Rognoni P, Barbiroli A, **Lavatelli F**, Russo R, Maritan M, Palladini G, Bolognesi M, Merlini G, Ricagno S. Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity. *Sci Rep*. 2017;7(1):16809.
11. Imperlini E, Gneccchi M, Rognoni P, Sabidò E, Ciuffreda MC, Palladini G, Espadas-Garcia G, Mancuso FM, Bozzola M, Malpasso G, Valentini V, Palladini G, Orrù S, Ferraro G, Milani P, Perlini S, Salvatore F, Merlini G, **Lavatelli F**. Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells. *Sci Rep*. 2017;7(1):15661.
12. **Lavatelli F**, Merlini G. How do we improve treatments for patients with amyloidosis using proteomics? *Expert Rev Proteomics*. *Expert Rev Proteomics*. 2017;14(7):561-563.
13. Milani P, Basset M, Russo F, Foli A, **Lavatelli F**, Nuvolone M, Ferraro G, Palladini G, Merlini G. Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome. *Amyloid*. 2017;24(sup1):64-65.
14. Basset M, Milani P, Russo F, **Lavatelli F**, Nuvolone M, Foli A, Perlini S, Palladini G, Merlini G. Patterns of relapse after upfront bortezomib therapy in AL amyloidosis. *Amyloid*. 2017;24(sup1):60-61.
15. Palladini G, Milani P, Basset M, Russo F, **Lavatelli F**, Nuvolone M, Ferraro G, Bozzola M, Foli A, Merlini G. Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis. *Amyloid*. 2017;24(sup1):68-69.
16. Russo F, Valentini V, Basset M, Bosoni T, Milani P, Ferraro G, Pirolini L, Foli A, **Lavatelli F**, Belvisi F, Consogno G, Nuvolone M, Li Bergolis F, Bozzola M, Albertini R, Palladini G, Merlini G. Identification

and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis. *Amyloid*. 2017;24(sup1):66-67.

17. Palladini G, Milani P, Basset M, Russo F, **Lavatelli F**, Nuvolone M, Ferraro G, Bozzola M, Foli A, Perlina S, Merlini G. Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response. *Amyloid*. 2017;24(sup1):54-55.
18. Palladini G, Riva E, Basset M, Russo F, Milani P, Pasquinucci E, Foli A, **Lavatelli F**, Nuvolone M, Casarini S, Obici L, Merlini G. Prognostication of survival and progression to dialysis in AA amyloidosis. *Amyloid*. 2017;24(sup1):136-137.
19. Nuvolone M, Sorce S, Pelczar P, Rushing E, **Lavatelli F**, Rognoni P, Valentini V, Palladini G, Merlini G, Aguzzi A. Regulated expression of amyloidogenic immunoglobulin light chains in mice. *Amyloid*. 2017;24(sup1):52-53.
20. Palladini G, Jaccard A, Milani P, Lavergne D, Foli A, Bender S, **Lavatelli F**, Bosoni T, Valentini V, Pirolini L, Ferraro G, Basset M, Russo F, Nuvolone M, Albertini R, Cogne M, Merlini G. Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays. *Clin Chem Lab Med*. 2017;55(11):1734-1743
21. **Lavatelli F**, Merlini G. Advances in proteomic study of cardiac amyloidosis: progress and potential. *Expert Rev Proteomics*. 2016:1-11.
22. Ami D, **Lavatelli F**, Rognoni P, Palladini G, Raimondi S, Giorgetti S, Monti L, Doglia SM, Natalello A, Merlini G. In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study. *Sci Rep*. 2016;6:29096.
23. Palladini G, Milani P, Foli A, Basset M, Russo F, Bosoni T, Pirolini L, Valentini V, Ferraro G, **Lavatelli F**, Barassi A, Albertini R, Merlini G. The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis. *Clin Chem Lab Med*. 2016;54(6):939-45.
24. Lavatelli F, di Fonzo A, Palladini G, Merlini G. Systemic amyloidoses and proteomics: The state of the art. *EuPA Open Proteom*. 2016;11:4-10.
25. Caccialanza R, Palladini G, Cereda E, Bonardi C, Milani P, Cameletti B, Quarleri L, Cappello S, Foli A, **Lavatelli F**, Klersy C, Merlini G. Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis. *Nutrition*. 2015;31(10):1228-34.
26. **Lavatelli F***, Imperlini E*, Orrù S, Rognoni P, Sarnataro D, Palladini G, Malpasso G, Soriano ME, Di Fonzo A, Valentini V, Gneccchi M, Perlina S, Salvatore F, Merlini G. Novel mitochondrial protein interactors of immunoglobulin light chains causing heart amyloidosis. *FASEB J*. 2015;29(11):4614-28.
27. Fernández de Larrea C, Verga L, Morbini P, Klersy C, **Lavatelli F**, Foli A, Obici L, Milani P, Capello GL, Paulli M, Palladini G, Merlini G. A practical approach to the diagnosis of systemic amyloidoses. *Blood*. 2015;125(14):2239-44.
28. Palladini G, Milani P, Foli A, Vidus Rosin M, Basset M, **Lavatelli F**, Nuvolone M, Obici L, Perlina S, Merlini G. Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients. *Leukemia*. 2014;28(12):2311-6.
29. **Lavatelli F**, Albertini R, Di Fonzo A, Palladini G, Merlini G. Biochemical markers in early diagnosis and management of systemic amyloidoses. *Clin Chem Lab Med*. 2014;52(11):1517-31.
30. Diomede L, Rognoni P, Lavatelli F, Romeo M, di Fonzo A, Foray C, Fiordaliso F, Palladini G, Valentini V, Perfetti V, Salmona M, Merlini G. Investigating heart-specific toxicity of amyloidogenic immunoglobulin light chains: A lesson from *C. elegans*. *Worm*. 2014;3(3):e965590.
31. Diomede L, Rognoni P, **Lavatelli F**, Romeo M, Del Favero E, Cantù L, Ghibaudi E, di Fonzo A, Corbelli A, Fiordaliso F, Palladini G, Valentini V, Perfetti V, Salmona M, Merlini G. A *Caenorhabditis elegans*-based assay recognizes immunoglobulin light chains causing heart amyloidosis. *Blood*. 2014;123(23):3543-52.
32. Palladini G, Milani P, Foli A, Obici L, **Lavatelli F**, Nuvolone M, Caccialanza R, Perlina S, Merlini G. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. *Haematologica*. 2014;99(4):743-50.
33. Rognoni P, **Lavatelli F**, Casarini S, Palladini G, Verga L, Pedrazzoli P, Valentini G, Merlini G, Perfetti V. A Strategy for Synthesis of Pathogenic Human Immunoglobulin Free Light Chains in *E. coli*. *PLoS One*. 2013;8(9):e76022.
34. Brambilla F, **Lavatelli F**, Di Silvestre D, Valentini V, Palladini G, Merlini G, Mauri P. Shotgun protein profile of human adipose tissue and its changes in relation to systemic amyloidoses. *J Proteome Res*. 2013;12(12):5642-55.
35. Caccialanza R, Palladini G, Klersy C, Cereda E, Bonardi C, Cameletti B, Quarleri L, Montagna E, Foli A, Milani P, **Lavatelli F**, Marena C, Merlini G. Malnutrition at Diagnosis Predicts Mortality in

- Patients With Systemic Immunoglobulin Light-Chain Amyloidosis Independently of Cardiac Stage and Response to Treatment. *JPEN J Parenter Enteral Nutr.* 2014;38(7):891-4.
36. Guan J, Mishra S, Shi J, Plovie E, Qiu Y, Cao X, Gianni D, Jiang B, Del Monte F, Connors LH, Seldin DC, **Lavatelli F**, Rognoni P, Palladini G, Merlini G, Falk RH, Semigran MJ, Dec GW Jr, Macrae CA, Liao R. Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. *Basic Res Cardiol.* 2013;108(5):378.
 37. Ihse E, Rapezzi C, Merlini G, Benson MD, Ando Y, Suhr OB, Ikeda SI, **Lavatelli F**, Obici L, Quarta CC, Leone O, Jono H, Ueda M, Lorenzini M, Liepnieks J, Ohshima T, Tasaki M, Yamashita T, Westermarck P. Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis. *Amyloid.* 2013 Sep;20(3):142-50.
 38. Brambilla F, **Lavatelli F**, Merlini G, Mauri P. Clinical proteomics for diagnosis and typing of systemic amyloidoses. *Proteomics Clin Appl.* 2013;7(1-2):136-43.
 39. Palladini G, Russo P, Milani P, Foli A, **Lavatelli F**, Nuvolone M, Perlini S, Merlini G. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. *Haematologica.* 2013;98(3):433-6.
 40. Brambilla F, **Lavatelli F**, Valentini V, Di Silvestre D, Obici L, Mauri P, Merlini G. Changes in tissue proteome associated with ATTR amyloidosis: insights into pathogenesis. *Amyloid.* 2012;19 Suppl 1:11-3.
 41. Palladini G, Foli A, Milani P, Russo P, Albertini R, **Lavatelli F**, Obici L, Perlini S, Moratti R, Merlini G. Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. *Am J Hematol.* 2012;87(5):465-71.
 42. **Lavatelli F**, Vrana JA. Proteomic typing of amyloid deposits in systemic amyloidoses. *Amyloid.* 2011;18:177-82.
 43. Palladini G, Barassi A, Perlini S, Milani P, Foli A, Russo P, Albertini R, Obici L, **Lavatelli F**, Sarais G, Casarini S, Moratti R, Melzi D, Eril GV, Merlini G. Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis. *Amyloid.* 2011;18:216-21.
 44. Brambilla F*, **Lavatelli F***, Di Silvestre D, Valentini V, Rossi R, Palladini G, Obici L, Verga L, Mauri PL, Merlini G. Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. *Blood.* 2012;119(8):1844-7. *Equal contribution
 45. Ferrari R, Caffi E, Quaglini S, Stefanelli M, Russo P, Palladini G, **Lavatelli F**, Merlini G. AMICA: an electronic patient record specifically designed for an amyloidosis network. *Amyloid.* 2011;18 S1:231-3.
 46. Panzarasa S, Quaglini S, Ferrari R, Stefanelli M, Foli A, Palladini G, Russo P, **Lavatelli F**. A workflow management system for the biological samples exchange within the amyloidosis network. *Amyloid.* 2011;18 S1:228-30.
 47. Perlini S, Musca F, Salinaro F, Fracchioni I, Palladini G, Obici L, Albertini R, Moratti R, **Lavatelli F**, Palladini G, Rapezzi C, Merlini G. Functional correlates of N-terminal natriuretic peptide type B (NT-proBNP) response to therapy in cardiac light chain (AL) amyloidosis. *Amyloid.* 2011;18 S1:91-2.
 48. **Lavatelli F**, Valentini V, Palladini G, Verga L, Russo P, Foli A, Obici L, Sarais G, Perfetti V, Casarini S, Merlini G. Mass spectrometry-based proteomics as a diagnostic tool when immunoelectron microscopy fails in typing amyloid deposits. *Amyloid.* 2011;18 S1:59-61.
 49. Valentini V, **Lavatelli F**, Obici L, Donadei S, Perlini S, Palladini G, Merlini G. Proteomic characterization of amyloid deposits in transthyretin amyloidosis associated with various mutations. *Amyloid.* 2011;18 S1:56-8.
 50. Caccialanza R, Palladini G, Klersy C, Cereda E, Bonardi C, Cameletti B, Montagna E, Russo P, Foli A, Milani P, **Lavatelli F**, Merlini G. Nutritional status independently affects quality of life of patients with systemic immunoglobulin light-chain (AL) amyloidosis. *Ann Hematol.* 2012;91:399-406.
 51. Palladini G, Russo P, Foli A, Milani P, **Lavatelli F**, Obici L, Nuvolone M, Brugnattelli S, Invernizzi R, Merlini G. Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. *Ann Hematol.* 2012;91:89-92.
 52. Palladini G, Foli A, Russo P, Milani P, Obici L, **Lavatelli F**, Merlini G. Treatment of IgM-Associated AL Amyloidosis With the Combination of Rituximab, Bortezomib, and Dexamethasone. *Clin Lymphoma Myeloma Leuk.* 2011;11:143-5.
 53. **Lavatelli F**, Brambilla F, Valentini V, Rognoni P, Casarini S, Di Silvestre D, Perfetti V, Palladini G, Sarais G, Mauri P, Merlini G. A novel approach for the purification and proteomic analysis of pathogenic immunoglobulin free light chains from serum. *Biochim Biophys Acta.* 2011;1814: 409-19.
 54. Obici L, Raimondi S, **Lavatelli F**, Bellotti V, Merlini G. Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. *Arthritis Rheum.* 2009;61:1435-40.

55. Palladini G, Russo P, Bosoni T, Sarais G, **Lavatelli F**, Foli A, Bragotti LZ, Perfetti V, Obici L, Bergesio F, Albertini R, Moratti R, Merlini G. AL amyloidosis associated with IgM monoclonal protein: a distinct clinical entity. *Clin Lymphoma Myeloma*. 2009;9:80-3.
56. Stoppini M, Obici L, **Lavatelli F**, Giorgetti S, Marchese L, Moratti R, Bellotti V, Merlini G. Proteomics in protein misfolding diseases. *Clin Chem Lab Med*. 2009;47:627-35.
57. Palladini G, Russo P, Bosoni T, Verga L, Sarais G, **Lavatelli F**, Nuvolone M, Obici L, Casarini S, Donadei S, Albertini R, Righetti G, Marini M, Graziani MS, Melzi D'Eril GV, Moratti R, Merlini G. Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine. *Clin Chem*. 2009;55:499-504.
58. Palladini G, Russo P, **Lavatelli F**, Nuvolone M, Albertini R, Bosoni T, Perfetti V, Obici L, Perlini S, Moratti R, Merlini G. Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. *Ann Hematol*. 2009;88:347-50.
59. **Lavatelli F***, Perlman DH*, Spencer B, Prokava T, McComb ME, Théberge R, Connors LH, Bellotti V, Seldin DC, Merlini G, Skinner M, Costello CE. Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. *Mol Cell Proteomics*. 2008;7:1570-83.
60. Palladini G, Russo P, Nuvolone M, **Lavatelli F**, Perfetti V, Obici L, Merlini G. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. *Blood*. 2007;110:787-8.
61. Bellotti V, Nuvolone M, Giorgetti S, Obici L, Palladini G, Russo P, **Lavatelli F**, Perfetti V, Merlini G. The workings of the amyloid diseases. *Ann Med*. 2007;39:200-7.
62. Caccialanza R, Palladini G, Klersy C, Cena H, Vagia C, Cameletti B, Russo P, **Lavatelli F**, Merlini G. Nutritional status of outpatients with systemic immunoglobulin light-chain amyloidosis. *Am J Clin Nutr*. 2006;83:350-4.
63. Palladini G, **Lavatelli F**, Russo P, Perlini S, Perfetti V, Bosoni T, Obici L, Bradwell AR, Melzi D'Eril G, Fogari R, Moratti R, Merlini G. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL amyloidosis. *Blood*. 2006;107:3854-8.
64. Palladini G, Perfetti V, Perlini S, Obici L, **Lavatelli F**, Caccialanza R, Invernizzi R, Comotti B, Merlini G. The combination of thalidomide and intermediate dose dexamethasone is an effective but toxic treatment for patients with AL (primary) amyloidosis. *Blood* 2005;105:2949-51.

Capitoli di libri

1. Lavatelli F, Brambilla F, Di Fonzo A, Ferraro G, Palladini G, Mauri PL, Merlini G. The Role of Differential Proteomics in Amyloid Typing: The Experience of the Pavia Referral Center. In: "Amyloid and Related Disorders. Surgical Pathology and Clinical Correlations", Chapter 24. Springer 2015. ISBN: 978-3-319-19294-9 DOI: 10.1007/978-3-319-19294-9
2. Lavatelli F, Palladini G, Merlini G. Pathogenesis of Systemic Amyloidoses. In: "Amyloidosis: Diagnosis and Treatment", Chapter 4, p. 49-64. Humana Press, 2010. ISBN: 978-1-60761-630-6 DOI 10.1007/978-1-60761-631-3

* **Co-first author**

** **Co-corresponding author**

Pavia, 17 giugno 2020

